Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US10960075B2 · kind B2 · utility
0Cited by
3References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 6, 2019 |
| Grant date | Mar 30, 2021 |
| Priority date | — |
| Expiry date | Nov 6, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.